What We Do:
The NIDA AIDS Workgroup facilitates the coordination of HIV/AIDS activities across the different divisions/centers/offices within NIDA. This workgroup has representatives from all of the divisions/centers/offices at NIDA and reflects the broad research areas that are supported by NIDA. Members of the workgroup are listed along with their programmatic interests. E-mail addresses are listed for program staff in the divisions to which AIDS applications are assigned. Please feel free to contact the appropriate program staff to discuss potential applications.
Center for Clinical Trials Network (CCTN)
- Raul Mandler - NIDA/CCTN HIV/AIDS Liaison
Division of Basic Neurosciences and Behavioral Research (DBNBR)
- Roger Sorensen - investigations of the neuropathology and neurological disorders caused by drug abuse and HIV/AIDS, including interactions of drugs of abuse, host and viral factors on neuronal and glial function, neuroplasticity, and the neuropathogenesis of neuronal, cognitive, and motor deficits due to drug abuse and HIV infection.
- Albert Avila - neuroimmune pharmacology and pathogenesis of HIV; effects of psychoactive drugs, withdrawal, stress, and infection on the immune response.
- Minda Lynch - laboratory-based animal investigations of the cognitive and behavioral antecedents for high-risk sexual behavior; and behavioral and cognitive consequences of HIV/AIDS.
- Vishnu Purohit - 1) mother-to-child transmission of HIV and drugs of abuse - placental injury, chemokine receptors, viral entry, viral replication, genetic and epigenetic factors, transplacental drug transporters, and drug to drug interaction; 2) progression of AIDS in adolescents and drugs of abuse; 3) HIV, liver disorders and lipid metabolism.
Division of Clinical Neuroscience and Behavioral Research (DCNBR)
- Lisa Onken - integrating HIV risk reduction into drug abuse treatment, developing and testing HIV risk reduction interventions for drug abuse treatment populations, behavioral interventions to promote adherence to HIV medications and/or treatment.
- Will Aklin - Neurobehavioral processes underlying HIV risk (impulsivity and risky decision-making) as treatment targets, behavioral and integrative treatments for HIV, integration of risk reduction strategies into drug abuse treatment, treatments that promote adherence to HIV medications.
- Cheryl Boyce - health and development of HIV-infected and HIV-affected children and adolescents including interventions; development of drug-related HIV risk behaviors in youth.
- Yu Lin - cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS; neuroinflammation; and co-morbidity.
Division of Epidemiology, Services, and Prevention Research (DESPR)
- Elizabeth Lambert - behavioral and social epidemiology and natural history research on HIV/AIDS and other infectious diseases among drug users, their social networks, and their communities; behavioral and molecular epidemiology of host and viral factors that increase risks for the acquisition and transmission of HIV and co-infections, including drug-resistant viruses.
- Richard Jenkins - behavioral and social aspects of preventive biomedical trials;; community, structural, and policy-level prevention interventions; international HIV prevention; innovative research methods and multi-method research designs; preventive intervention with men who have sex with men; prevention interventions with co-morbid populations Dionne Jones - treatment services for HIV/AIDS patients, including women and minorities and those at risk of infection; HIV/AIDS interventions and health and behavioral outcomes.
- Jeff Schulden - the association between psychiatric illness and substance abuse among adults, with a particular focus on the association between substance abuse and PTSD, trauma, and stress; intimate partner violence and substance use disorders; suicide and overdose; and comorbid mental health and substance use disorders among persons living with HIV.
- Shoshana Kahana - behavioral interventions for comorbid conditions, specifically traumatic stress and drug use, in adolescent and adult populations; integrating HIV risk reduction into drug abuse treatment; and the development and effective implementation of interventions that promote treatment adherence in populations with chronic health conditions, including HIV.
Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA)
- Jag Khalsa - medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis (HCV), STDs, TB, and others; interactions between drugs of abuse and medications used in the treatment of drug addiction.
- Guifang Lao - medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis C/B, and STDs/STIs; developing innovative research program of non-invasive techniques/methodologies for studying the medical consequences of drug abuse and co-occurring HIV, hepatitis and others infections.
International Program (IP)
- Steve Gust - international activities related to characterizing the links between drug abuse and HIV/AIDS, including its transmission and prevention
Intramural Research Program (IRP)
- Karran Phillips - mobile health (mHealth) approaches to the integration of addiction treatment with HIV and HCV risk reduction and HIV, HCV, and primary care
Office of Extramural Affairs (OEA)
- Mark Green
Office of Planning and Research Management (OPRM)
- Stacy Gardner
Office of Science Policy and Communications (OSPC)
- Michele L. Rankin
Women and Gender Research (WGRG)
- Cora Lee Wetherington - women, girls, and gender differences and HIV/AIDS
- Samia Dawud Noursi - Sex/Gender Differences; Women's Health; HIV/AIDS; Children's Social and Emotional Development; Child Maltreatment; Domestic Violence
- Jacques Normand, Ph.D. - Chair, Director: AIDS Research Program